Hepatitis B virus (HBV) infection shows significant gender-related differences in pathogenesis, disease progression, and development of hepatocellular carcinoma. The gender-associated differences in HBV replication and viral protein levels may be associated with distinct HBV-specific immune responses in the host. In the present study, we examined the impact of gender on HBV-specific immune responses in two different mouse models representing transient and persistent hepadnaviral infection; hydrodynamic injection with the HBV genome mimicked acute HBV infection, whereas the efficacy of therapeutic vaccination was studied in the woodchuck hepatitis virus transgenic mouse model. Consistent with previous reports, significantly higher HBV DNA and protein levels were detected in male compared to female mice. Although hydrodynamic injection with the HBV genome resulted in similar numbers of intrahepatic HBV-specific cluster of differentiation 8-positive (CD8 1 ) T cells, their functionality was significantly reduced in males and correlated with higher numbers of intrahepatic regulatory T cells (Tregs). Similar effects were observed in woodchuck hepatitis virus transgenic mice immunized with a DNA prime-recombinant adenovirus boost vaccination protocol. Male mice showed functionally suppressed woodchuck hepatitis virus-specific CD8 1 T-cell responses in the liver and significantly higher numbers of intrahepatic Tregs compared to females. Blockade of Treg responses in male mice led to augmented effector functions of specific CD8 1 T cells and subsequently improved virus control in both models of transient and persistent hepadnaviral infection.
I nfection with hepatitis B virus (HBV) may lead to subclinical, acute, or chronic hepatitis B. Persistent HBV infection is one of the main causes of liver cirrhosis and hepatocellular carcinoma worldwide. (1) From clinical practice, it is known that gender is one of the major factors that influence the outcome and severity of HBV infection. (1, 2) Case-cohort epidemiological studies in Taiwan showed that men are more prone to become chronic HBV carriers and show higher HBV prevalence than women (10.7% versus 4.4%). (3) Abbreviations: AdV, recombinant adenovirus; ALT, alanine aminotransferase; ARE, androgen responsive element; CD, cluster of differentiation; Foxp3, forkhead box P3; GzmB, granzyme B; HBcAg, HBV core antigen; HBeAg, HBV e antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus; HI, hydrodynamic injection; ICS, intracellular cytokine staining; IFN-c, interferon-gamma; IL-2, interleukin-2; LIL, liver-infiltrating lymphocyte; PD-1, programmed cell death-1; sAg, surface antigen; Tg, transgenic; TNF-a, tumor necrosis factor-alpha; Treg, regulatory T cell; WHcAg, WHV core antigen; WHV, woodchuck hepatitis virus; WT, wild type; Wtg, WHV transgenic mice; WtgS -, Wtg mice lacking sAg.
Moreover, men tend to have higher serum HBV loads than women. (1) Elevated HBV replication and higher serum HBV levels belong to the main risk factors for HBV-related carcinogenesis.
(1) Consistently, HBVrelated hepatocellular carcinoma occurs 5-7 times more frequently in male than female patients. (2) These observations clearly indicate that HBV infection and pathogenesis may be modulated by sex hormones. Recently, Wang et al. identified two androgen responsive elements (AREs) within the HBV enhancer I, which are conserved in different HBV genotypes. Binding of the androgen receptor complex to the AREs leads to increased HBV transcription and thereby enhances HBV replication and protein expression. (4) By contrast, estrogen showed negative effects on HBV replication. Interaction of estrogen with nuclear estrogen receptor a and hepatocyte nuclear factor 4a reduced HBV mRNA levels by suppressing the activity of viral enhancer I. (5) Thus, contrary molecular effects of androgens and estrogens on HBV transcription may partially explain the sex disparity in the progression of HBV-associated liver disease.
The effective adaptive immune response to HBV plays a crucial role in the control of HBV infection (6, 7) and may be a factor responsible for the gender-related discrepancies in HBV infection. Indeed, prophylactic vaccination against HBV induces higher HBV surface antigen (HBsAg)-specific antibody titers in women than men. (3) A higher percentage of female asymptomatic chronic HBV carriers clear HBV e antigen (HBeAg) and HBsAg and seroconvert to HBeAg and HBsAg antibodies than males. (8) In addition, the functionality of effector cluster of differentiation 8-positive (CD8 1 ) T cells may be influenced by the levels of viral antigens produced by hepatocytes. (9) Therefore, genderrelated differences in HBV replication and gene expression may influence the priming and function of HBVspecific T cells. However, the mechanisms involved in gender-related differences with respect to the HBVspecific T-cell response were not investigated.
Regulatory T cells (Tregs), characterized by expression of forkhead box P3 (Foxp3) transcription factor, are known to suppress the proliferation and effector functions of T and B cells. (10) Some studies underline the significance of Tregs in the pathogenesis of HBV infection. (11) (12) (13) Tregs may be involved in genderrelated differences in progression and severity of viral infections such as human immunodeficiency virus infection (14) and acute coxsackievirus B3-induced myocarditis. (15) Whether Tregs play a role in mediating the gender-associated differences in HBV infection and pathogenesis has not been studied so far.
In this study, we investigated whether genderrelated differences in HBV replication and gene expression may determine the priming of HBVspecific T-cell responses and viral control. Two mouse models of acute and persistent hepadnaviral infection were explored. Hydrodynamic injection (HI) with the HBV genome results in transient HBV replication in the mouse liver and viral clearance within 2-4 weeks, thereby mimicking acute HBV infection. (16) Woodchuck hepatitis virus (WHV) transgenic (Tg) mice (Wtg) (17) served as a model of persistent hepadnaviral infection and were used to test therapeutic vaccination approaches. (18) Both models showed gender-related differences in hepadnaviral replication that reflect the situation in humans: viral replication was higher in males than in females. (17, 19) Therefore, we explored these mouse models to study the gender-related differences in the virus-specific immune responses and therapeutic vaccination.
Materials and Methods

ETHICAL STATEMENT
Animal experiments were conducted in strict accordance with the German regulations of the Society for Laboratory Animal Science (GV-SOLAS) and the European Health Law of the Federation of Laboratory Animal Science Associations (FELASA). Experiments were approved either by the local Animal Care and Use Committee (Animal Care Center, University of Duisburg-Essen, Essen, Germany and the district government of D€ usseldorf, Germany; permission numbers G1117/10, G1236/11 and G1204/12) or by the Ethics Committee of the Shanghai Public Health Clinical Center (Shanghai, PR China; permission number: 2014-K003). All efforts were made to minimize suffering. ) and previously characterized. (17) WHV tg mice were 10 to 12 weeks old at the beginning of experiments. Mice were kept under in pathogen-free (SPF) and biosafety level 2 environments at the Animal Facility, University Hospital of Essen, University of Duisburg-Essen or Animal Center of Laboratory Animals, Shanghai Public Health Clinical Center. The experiments were performed during the light phase of the day.
LABORATORY ANIMALS
HBV HYDRODYNAMIC INJECTION (HI)
Ten micrograms of replication competent HBV plasmids were diluted in PBS volume corresponding to 10% of mouse body weight and then injected into the tail veins of mice in 6-8 seconds. HI was performed with pSM2 plasmid (harboring a head-to-tail tandem dimeric HBV genome (GenBank accession number: V01460) or HBV plasmid in which critical residuals responsible for androgen binding in ARE were mutated (ARE-MUT) and corresponding WT plasmid.
IMMUNIZATION OF WHV TRANSGENIC MICE WITH DNA PRIME -AdV BOOST REGIMEN
Mice were pretreated by intramuscular injection of 50 ml of cardiotoxin (10 mM in PBS; Latoxan, Valence, France) into Tibialis anterior muscle 1 week before the immunization. Mice were then immunized twice with 100 mg of pCGWHc plasmid at days 0 and 14 and boosted at day 42 with 2 3 10 9 PFU of Ad5WHc.
FUNCTIONAL BLOCKADE OF Tregs AND Treg DEPLETION
Tregs were functionally blocked by intraperitoneal injection of 125 mg of rat anti-mouse CD25 IgG1 antibody (clone PC-61.5.3, BioXCell; West Lebanon, NH, USA). As an isotype control rat IgG1 antibody was used (clone HRPN, BioXCell, West Lebanon, NH, USA). To deplete Tregs in DEREG mice, 0.5 lg of diphtheria toxin (Merck, Darmstadt, Germany) was injected intraperitoneally at days 10, 12 and 14 after HI.
ISOLATION OF MURINE SPLENIC AND HEPATIC LYMPHOCYTES
Preparation of a single-cell suspensions of murine splenocytes and hepatic lymphocytes were performed according to the procedure described previously. (18) Briefly, liver was perfused with PBS (to flush blood from the hepatic vasculature) and forced through a 70 mm nylon cell strainer (BD Falcon, Franklin Lakes, NJ). After washing, cell pellets were suspended in 5 lml of prewarmed enzyme solution, containing 0,05% Collagenase type II (Sigma) and 500 U/ml DNAse type I (Sigma) in Ca 2+ /Mg 2+ -free HBSS supplemented with 10% FBS, and digested for 40 min at 378C. Cells were then layered on 40% Percoll solution (Sigma) in RPMI 1640 supplemented with 10 U/ml penicillin-streptomycin for density separation, and centrifuged at 300 3 g for 20 minutes at 48C without brakes. Up to 1 3 10 6 of isolated lymphocytes per well were plated in 96-well plates in 200 ml of cell culture medium. Lymphocytes were then stimulated for 6 hours with K 
HBV/WHV DNA ANALYSIS AND SEROLOGY
WHV and HBV DNA were extracted using QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's protocol. The viral DNA was quantified by real-time PCR with a Platinum SYBR Green Kit (Invitrogen) using LightCycler thermocycler (Roche). The WHV-specific primers used for the PCR were wc1 (5 0 -TGG GGC CAT GGA CAT AGA TCC TTA-3 0 ) and wc-149s (5 0 -AAG ATC TCT AAA TGA CTG TAT GTT CCG-3 0 ). The HBV-specific primers used for the PCR were Hope Fwd (5 0 -GTT GCC CGT TTG TCC TCT AAT TC-3 0 ) and Hope Rev (5 0 -GGA GGG ATA CAT AGA GGT TCC TT-3 0 ). Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) were quantified by standard diagnostic procedures.
STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software Inc., San Diego, CA). Statistical differences were analyzed by: Student t test, Mann-Whitney test, parametric one-way ANOVA, nonparametric Kruskal-Wallis test, or Wilcoxon signed rank test. The P values < 0.05 were considered significant.
Detailed description of Material and Methods is provided for the reader in the Supporting Information.
Results
DECREASED FUNCTIONALITY OF HBV-SPECIFIC CD8 1 T CELLS IN MALE MICE AFTER HBV HI CORRELATES WITH INCREASED NUMBERS OF INTRAHEPATIC Tregs
To investigate the impact of gender-related differences in HBV replication on virus-specific T-cell responses during transient HBV infection, we performed HI with the pSM2 plasmid (containing a 2-fold HBV genome) using male and female C57BL/ 6 mice. The serum HBV DNA load, HBsAg and HBeAg levels, as well as liver alanine aminotransferase (ALT) levels were monitored for 28 days post-HI.
Male mice had significantly higher and longer viremia than female mice. At day 21 post-HI, serum HBV DNA loads in all 11 females were below the detection limit, whereas 7 out of 11 males were still HBV-positive (P < 0.05) (Fig. 1A , upper panel). Serum HBsAg levels peaked at day 4 post-HI, then decreased and became undetectable in most of the mice at day 14 post-HI (Fig. 1A , middle panel), while still partly detectable in the liver (Supporting Fig. S1 ). HBsAg levels were significantly higher in males compared to females at days 4 and 7 post-HI (P < 0.0001 and P < 0.001, respectively). HBeAg was detectable in mouse sera up to day 21 post-HI (Fig. 1A , lower panel). Similar to HBsAg, HBeAg levels were generally higher in male than in female mice, with significant differences at days 4 and 14 post-HI (P < 0.001 and P < 0.05, respectively).
It is known that an initial decrease in HBV DNA and antigen levels during the first week after HBV HI is not related to T-cell responses but is rather a spontaneous loss or inactivation of the injected HBV genome. However, the HBV-specific T-cell response is crucial for the final resolution of infection. (20) The peak ALT elevation coincident with viral clearance, likely reflecting T cellmediated liver damage, was detected not earlier than day 21 after HI ( Fig. 1B) . Therefore, days 14, 21, and 28 post-HI were chosen to compare intrahepatic HBVspecific CD8
1 T-cell responses in mice. First, we analyzed the numbers of HBV-specific CD8 1 T cells ex vivo, using dimers loaded with an HBV core antigen (HBcAg)-derived epitope peptide (C93) and the strategy presented in Supporting Fig. S2 . The numbers of intrahepatic C93-specific CD8 1 T cells (Fig. 1C , upper panel, and F) peaked at day 21 post-HI. Only slight but not statistically significant differences in the numbers of C93-specific CD8
1 T cells were observed between male and female mice. Next, the effector functions of HBV-specific CD8
1 T cells in male and female mice were compared. Intracellular interferon-gamma (IFN-c) staining of liver-infiltrating lymphocytes (LILs) stimulated with the C93 peptide showed that the numbers of IFN-c-positive CD8
1 T cells in females corresponded to the expansion of HBV-specific CD8 1 T cells, reaching peak levels at day 21 post-HI (Fig. 1C , middle panel, and F). However, the numbers of HBVspecific IFN-c 1 CD8 1 T cells in males were significantly lower (P < 0.01) at day 21 post-HI and increased only slightly 7 days later. Similar findings were obtained for intrahepatic HBsAg-specific CD8 1 T cells (Supporting Fig. S3 ). The cytolytic function of liver-infiltrating CD8 1 T cells was evaluated by intracellular staining of granzyme B (GzmB). Females showed higher numbers of GzmB 1 CD8 1 T cells in the liver than males at day 14 post-HI (P < 0.001) (Fig. 1C , lower panel; original data in Supporting Fig. S4 ). Numbers of GzmB 1 CD8
1
T cells increased slightly in males at day 21 but then dropped to low levels in all mice at day 28 post-HI. These results suggest that the functionality of HBV-specific T cells in male mice was negatively regulated at days 14 and 21 post-HI. However, the selected activation and exhaustion markers CD44, CD62 ligand, and programmed cell death-1 (PD-1) on intrahepatic HBVspecific CD8 1 cells were found to be not significantly different in female and male mice (Supporting Fig. S5 ).
It is known that Tregs inhibit the function of effector T cells; thus, we determined the kinetics of intrahepatic Treg numbers after HBV HI. Interestingly, the numbers of intrahepatic Tregs were significantly higher in males than in females at day 21 post-HI (P < 0.01) (Fig. 1D,F) . Moreover, we observed an inverse correlation between the numbers of intrahepatic IFN-c 1 C93-specific CD8 1 T cells and Tregs at day 21 post-HI (P < 0.05), irrespectively of gender (Fig. 1E) . Therefore, Tregs may be responsible for the reduced functionality of intrahepatic CD8 T cells in male mice.
These gender-related differences may be based on differences in the immune system or a result of increased HBV replication in male mice. A replication-competent HBV genome with a mutation within the ARE (ARE-MUT) was used for HI and compared with the corresponding wild-type (WT) HBV genome. (4) The ARE sequence enhances HBV replication in response to androgen and is likely responsible for higher HBV levels in male patients. The mutation abolishes the function of ARE in the HBV genome. As expected, the ARE mutation resulted in similar HBV replication levels in male and female C57BL/6 mice after HI, a clear difference from WT HBV plasmid injection ( Fig. 2A) . Accordingly, the HBV HI with WT, but not ARE-MUT, resulted in significant gender-related differences in the numbers of IFN-c 1 HBcAg-specific CD8 1 T cells and intrahepatic Tregs (Fig. 2B ). These data confirm that differential immune responses detected in male and female mice after HI are related to the androgenmediated differences in HBV replication in vivo.
BLOCKADE OF Treg RESPONSES IMPROVES HBV-SPECIFIC CD8
1
T-CELL RESPONSES AND ACCELERATES VIRAL CLEARANCE IN MALE MICE AFTER HBV HI
To clarify whether intrahepatic Tregs indeed functionally suppress HBV-specific CD8 1 T cells in males after HI, Tregs were blocked by anti-CD25 antibody treatment before performing HI (details in Supporting Information). Male C57BL/6 mice received anti-CD25 or isotype control antibody and 1 cell populations in total CD8 1 or CD25 1 T cells for day 21 post-HI (F). Asterisks mark significant differences: *P < 0.05, **P < 0.01, ***P < 0.005. Abbreviations: GE, genome equivalent; S/CO, sample per control; ICS, intracellular cytokine staining.
then HI with HBV pSM2 plasmid 1 day later. The impact of the Treg blockade on HBV clearance and immunity was monitored for 21 days post-HI.
Treatment with anti-CD25 or isotype control antibody did not result in a significant difference of HBV DNA, HBsAg, and HBeAg levels in mice until day 17 (Fig. 3A) . Males that received anti-CD25 antibody cleared HBV DNA from the peripheral blood at day 21, significantly faster than controls (P < 0.01). In addition, significantly higher serum ALT levels were detected in males treated with anti-CD25 compared to the isotype control at day 21 post-HI (P < 0.005) (Fig. 3B) . Therefore, T-cell responses in the liver of mice were analyzed at day 21 post-HI.
The blockade of Treg responses by anti-CD25 antibody resulted in a >40% reduction of intrahepatic Treg numbers (P < 0.05) (Fig. 3C) . Analysis of LILs, using C93-loaded dimers ex vivo, showed no statistically significant differences in the numbers of intrahepatic HBcAg-specific CD8
1 T cells between the groups (Fig. 3D, upper panel) . However, the functionality of HBV-specific CD8
1 T cells was significantly improved in males by anti-CD25 antibody treatment. Numbers of HBcAg-specific IFN-c 1
CD8
1 T cells were significantly higher in mice treated with anti-CD25 antibody than in controls (P < 0.005) (Fig. 3D, middle panel) . This was also true for intrahepatic GzmB 1 CD8 1 T cells after anti-CD25 antibody treatment (P < 0.05) (Fig. 3D, lower panel) . The functionally improved HBV-specific CD8 1 T-cell response after Treg blockade correlated with faster viral clearance post-HI in male mice. Moreover, we also performed highly specific depletion of Tregs in the DEREG mouse model after HBV HI. Previously, we showed that the numbers and the activation of liver CD8
1 T cells significantly increased after Treg depletion in HBV HI male mice. (11) Here, we show that Treg depletion in male DEREG mice also resulted in increased percentages of IFN-c 1 CD8 1 T cells in the spleen and the liver post-HI (Supporting Fig. S6) .
Interestingly, HBV injection combined with depletion of Tregs did not result in differences in   FIG. 2 . HBV-specific immune responses after HI with HBV ARE-MUT. HI was performed in male (n 5 5) and female (n 5 6) C57BL/6 mice, using a plasmid HBV ARE-MUT or corresponding WT plasmid. The kinetics of serum HBV DNA in mice is shown after HI with WT plasmid (A, upper) and ARE-MUT (A, lower). Numbers of intrahepatic IFN-c 1 CD8 1 T cells (B, upper) and Tregs (B, lower) detected ex vivo at day 28 after HI. Asterisks mark significant differences: *P < 0.05, ***P < 0.005. Abbreviations: GE, genome equivalent; n.d., not done; ns, not significant.
HBV parameters and intrahepatic HBV-specific Tcell responses between anti-CD25 or isotype antibody-treated female mice (Supporting Fig. S7 ), indicating that the Treg response is only critical in male mice. No change in activation status of the HBVspecific CD8
1 T cells after anti-CD25 treatment was observed between female and male mice (Supporting Fig. S8 ). T cells (D, lower) detected ex vivo at day 21 post-HI. Asterisks mark significant differences: *P < 0.05, **P < 0.01. Abbreviations: GE, genome equivalent; ns, not significant; S/CO, sample per control.
THE EFFICACY OF THERAPEUTIC VACCINATION IN Wtg MICE ALSO INVERSELY CORRELATES WITH NUMBERS OF INTRAHEPATIC Tregs
We recently showed that therapeutic vaccination elicits potent CD8
1 T-cell responses and reduces WHV replication in 1217 Wtg mice. (18) We also observed gender-related differences in WHV replication in these Tg mice.
(17) Therefore, we chose this mouse model to study the impact of gender on the efficacy of a therapeutic vaccination against hepadnaviral infection.
Consistent with previous findings, naive female Wtg mice showed significantly lower basal WHV DNA levels compared to males (Supporting Fig.  S9A ), as well as lower basal ALT levels (Supporting Fig. S9B ). Wtg mice were immunized by a heterologous DNA prime-recombinant adenovirus (AdV) boost regimen using vaccines expressing WHV core antigen (WHcAg) (Fig. 4A) , using a DNA plasmid (pCGWHc) and a recombinant AdV serotype 5 (Ad5WHc). (21) WHcAg-specific immune responses and WHV replication in Wtg mice were compared between males and females 2 weeks postimmunization.
First, intrahepatic HBV-specific CD8 1 T cells in naive and immunized Wtg mice were analyzed using dimers loaded with WHcAg-derived peptide wc13-21. The therapeutic vaccination induced an expansion of WHcAg-specific CD8 1 T cells in Wtg mice (P < 0.001 compared to naive Wtg mice), with no statistically significant difference between the genders (12 males versus 11 females) (Fig. 4B, 1 and TNF-a 1 WHcAg-specific CD8 1 T cells after immunization were significantly lower in males compared to females (P < 0.001 and P < 0.01, respectively) (Fig. 4C, upper panel, and E) . The same was true for multifunctional CD8
1 T cells producing several cytokines (P < 0.01) (Fig. 4C, lower panel) .
Nonvaccinated male Wtg mice had significantly higher numbers of GzmB 1 CD8 1 T cells than females (P < 0.05) (Fig. 4B, middle panel, and E) , correlating with the increased baseline ALT values in males. The immunizations increased the numbers of intrahepatic GzmB 1 CD8 1 T cells more strongly in females compared to males (P < 0.01). Further, higher numbers of intrahepatic Tregs were detected in male nonvaccinated Wtg mice compared to females (P < 0.05), as well as in immunized mice (P < 0.01) (Fig. 4B, lower panel, and  E) . Numbers of intrahepatic Tregs inversely correlated with those of IFN-c 1 WHcAg-specific CD8 1 T cells after the therapeutic vaccination (P < 0.05), irrespective of gender (Fig. 4D) . Phenotypic analysis of intrahepatic WHcAg-specific CD8
1 cells with CD44, CD62 ligand, and PD-1 markers showed no significant difference between males and females (Supporting Fig. S10 ).
Serum WHV loads were monitored before the first immunization (week -1) and at the time point of sacrifice (week 8). Therapeutic vaccination significantly reduced viral loads in both male and female mice (P < 0.005 and P < 0.0005, respectively). However, females showed significantly lower mean viral loads than males (P < 0.05) (Fig. 4F) . Only 3 out of 18 females (16.7%) but 9 out of 18 males (50%) remained positive for serum WHV DNA after vaccination.
Male Wtg mice mounted a less functional WHcAgspecific CD8
1 T-cell response in the liver after the therapeutic vaccination than female mice, correlating with higher numbers of intrahepatic Tregs and less efficient control of WHV replication. These differences were not observed if non-Tg C57/BL6 mice were immunized (unpublished data), indicating that gender-related differences observed in Wtg mice were related to the presence of WHV (see below).
BLOCKADE OF Treg RESPONSES IMPROVES THE EFFICACY OF THE THERAPEUTIC VACCINATION IN MALE Wtg MICE
Assuming that Tregs negatively regulate WHVspecific CD8
1 T-cell responses in male Wtg mice, we attempted to enhance specific T-cell responses by blocking Tregs using anti-CD25 antibody treatment during the therapeutic vaccination. At 1-2 days before each immunization mice received anti-CD25 or isotype control antibody. The intrahepatic WHcAg-specific immune response and WHV replication in Wtg mice were evaluated 2 weeks after the last immunization (Fig. 4A) .
The combination of therapeutic immunization and anti-CD25 antibody treatment resulted in lower numbers of intrahepatic Tregs compared to isotype control antibody treatment (Fig. 5A) . The anti-CD25 antibody treatment markedly increased the numbers of intrahepatic specific CD8 dimers in male Wtg mice (P < 0.05) (Fig. 5B , upper panel). Moreover, the anti-CD25 antibody treatment restored the functionality of intrahepatic CD8 1 T cells after the therapeutic vaccination. Numbers of intrahepatic GzmB 1 CD8 1 T cells were significantly higher in male mice that received anti-CD25 antibody than in the isotype control group (P < 0.05) (Fig. 5B, lower panel) . Similarly, significantly higher numbers of intrahepatic IFN-c 1 and TNF-a 1 WHcAg-specific CD8 1 T cells were detected in the anti-CD25 group (P < 0.01 and P < 0.05, respectively) (Fig. 5C, upper panel) , as well as for the subpopulation of wc13-21-specific CD8
1 T cells producing two cytokines (P < 0.05) (Fig. 5C, lower panel) . More effective CD8
1 T-cell responses resulted in increased serum ALT levels in male Wtg mice that received anti-CD25 antibody than in controls (P < 0.0005) (Fig. 5D) . Finally, the anti-CD25 antibody treatment further reduced WHV DNA levels after the therapeutic immunization when compared with isotype antibody treatment (2.58 3 10 3 versus 1.86 3 10 5 genome equivalents/mL) (Fig. 5E ). Taken together, these results clearly show that the blockade of Tregs improved the functionality of WHV-specific CD8
1
T cells and the overall efficacy of the therapeutic immunization in males.
The corresponding experiment performed in female Wtg mice showed no differences in WHV titers and intrahepatic virus-specific T-cell responses between the anti-CD25 and isotype antibody groups (Supporting Fig. S11 ). No change in CD44 and PD-1 expression on intrahepatic WHcAg-specific CD8
1 T cells after anti-CD25 treatment was observed in both female and male mice (Supporting Fig. S12 ).
SURFACE ANTIGEN EXPRESSION INCREASES INTRAHEPATIC Treg NUMBERS IN WHV Tg MICE
Hepadnaviral surface antigens (sAg) may play an important role in HBV pathogenesis and influence HBV-specific T-cell responses. HBsAg might interfere with the function of dendritic cells and induce myeloid-derived suppressor cells. (22) Interestingly, it was shown in patients and several mouse models of HBV infection that males have higher sAg levels than females. (19, 23) Therefore, we investigated the impact of sAg expression on WHV-specific T-cell responses and intrahepatic Treg numbers after the therapeutic vaccination using the 1281 Wtg mouse strain that lacks expression of sAg (designated further as WtgS -mice). In this strain WHV particles are not shed into the bloodstream. Male WtgS -mice show stronger WHV replication in the liver than females (17) and elevated ALT levels (Supporting Fig. S13A ). Male and female WtgS -mice were immunized with the heterologous DNA prime-AdV boost regimen as described above (Fig. 4A) . The WHcAg-specific CD8
1 T-cell response and Treg numbers in the liver of the mice were analyzed 2 weeks after immunization.
Therapeutic vaccination induced similar numbers of intrahepatic Tregs (Fig. 6A, upper panel) and WHcAg-specific CD8 1 T cells, (Fig. 6A , middle panel) (P < 0.001, compared to naive WtgS -mice) and intrahepatic GzmB 1 CD8 1 T cells (Fig. 6A , lower panel) in male and female WtgS -mice. In addition, intracellular IFN-c, TNF-a, and IL-2 staining of LILs after stimulation with wc13-21 peptide showed similar results for male and female WtgS -mice (Fig. 6B) .
These results suggest that expression of the hepadnaviral sAg may influence the expansion of Tregs in the liver and subsequently suppress virus-specific T-cell responses. HI with HBV genome lacking HBsAg expression delivered supporting data for this conclusion (Supporting Fig. S13B,C) .
Discussion
Here, we demonstrate that gender had a significant impact on hepadnaviral replication and, thereby, immune control in mouse models representing transient and persistent hepadnaviral infection. Levels of 1 T cells by staining with dimer wc13, intracellular IFN-c, TNF-a, and GzmB and Tregs by CD25 and Foxp3 staining (E). Serum WHV DNA loads before and after the immunization in male and female Wtg mice (F). Asterisks mark statistically significant differences: *P < 0.05, **P < 0.01, ***P < 0.005. Abbreviations: GE, genome equivalent; ICS, intracelluar cytokine staining; ns, not significant. hepadnaviral replication and gene expression influenced intrahepatic virus-specific T-cell responses by modulating the numbers of Tregs in the liver. In the HBV HI mouse model, HBV-specific CD8 1 T cells were primed in similar numbers and phenotype but differed significantly in their functionality between the genders, directly correlating to the Treg numbers. HBV clearance in both genders concurred with the rise of effective HBV-specific immune responses. However, HBV-specific CD8
1 T cells gained their functionality with a delayed kinetics in males compared to females, causing prolonged HBV replication in males. Similar effects were observed in Wtg mice immunized with a DNA prime-AdV boost regimen. Males showed lower and functionally less active CD8
1 T-cell responses to WHcAg in the liver and significantly higher numbers of intrahepatic Tregs compared to females. Moreover, suppression of WHV replication by therapeutic vaccination was less effective in male than female mice. Functional blockade of Tregs in male mice led to an improvement of effector functions of virus-specific CD8
1 T cells and viral control in both tested animal models. These findings show that Tregs reduce the effectiveness of hepadnavirus-specific immune responses and may contribute to viral persistence, especially in the male gender. T cells (C, lower) detected ex vivo after therapeutic vaccination. ALT levels (D) and WHV loads (E) detected in the serum of mice after therapeutic vaccination. Asterisks mark statistically significant differences: *P < 0.05, **P < 0.01, ***P < 0.005. Abbreviations: GE, genome equivalent; ns, not significant.
Tregs have been shown to play an important role in the pathogenesis of persistent HBV infection (12, 24) and the progression of chronic liver disease. (25, 26) It is suggested that higher HBV replication may influence the induction of specific immunity to HBV. (27) It was shown that reduction of HBV replication by antiviral treatment caused a decrease in circulating Tregs accompanied by partial restoration of HBV-specific immune response in chronic HBV patients. (28) Thus, the results of our study fully reflect the clinical observation and explain the severity of HBV infection in male patients.
Previously, the proportion of intrahepatic Tregs was found to be 5%-15% of liver-infiltrating CD4 1 T cells at the peak level at day 21 post-HI, suggesting that Tregs are mainly recruited into the liver with other immune cells after HI. (11) The appearance and expansion of Tregs at a specific site may be dependent on the presence of effector CD8 1 T cells. (29) Our results support this hypothesis as the kinetics of intrahepatic HBV-specific CD8
1 T-cell expansion correlated with Treg numbers during days 14-28 post-HI (Fig. 1C,D) . The suppressive effect of Tregs could be mediated by different mechanisms including production of anti-inflammatory cytokines, cytotoxic T lymphocyte antigen-4 expression, competitive consumption of IL-2, or production of cyclic adenosine monophosphate to down-regulate T-cell functions through direct cell-to-cell contacts. (30) It remains to be examined which mechanisms are operative in the control of HBV-specific T-cell immunity.
Some studies indicate that secretory HBeAg and HBsAg can interfere with HBV-specific immune responses. (31) Here, we showed that a lack of hepadnaviral sAg led to low numbers of Tregs in both HI and Wtg mice. HBsAg is expressed in large quantities in hepatocytes and secreted into the peripheral blood, which may lead to strong inflammation and influx of immune cells into the liver. (30) In the current study, we found that high levels of hepadnaviral sAg may play an important role in triggering Treg expansion. Nevertheless, how HBsAg influences the recruitment of Tregs needs further investigation. In many studies, responding Tregs were found not to be virusspecific (30) or to have extremely low numbers of virusspecific Tregs. (29) The immunomodulatory role of Tregs during acute viral infections is dual. Tregs prevent severe inflammation and immunopathology (32) but also interfere with viral clearance. (33) In our study, functional blockade of Tregs by anti-CD25 antibody during transient HBV infection and therapeutic vaccination resulted in increased numbers of IFN-c 1 CD8 1 T cells (2.9-fold and 2.1-fold, respectively) and GzmB 1 CD8 1 T cells (1.3-fold and 2.2-fold, respectively). This was associated with strong reduction in HBV/WHV viral loads, confirming that overall both noncytolytic and cytolytic CD8
1 T-cell effector functions contribute to viral clearance. (6, 7) Nevertheless, only mild elevations of ALT values were observed, underlying the importance of IFN-c as the first line of defense in acute and chronic hepadnaviral infections, as generally proposed. (31) Highly effective depletion of Tregs in DEREG mice during HI also improved HBV-specific T-cell functions, although with severely increased liver damage. (11, 13) Thus, carefully balanced modulation of Treg functions, e.g., by triggering IFN-c secretion, may facilitate viral control without accelerated liver damage in the context of chronic HBV infection. Moreover, PD-1 expression appears not to be a key determinant for the immunological differences seen between the genders, though it may contribute to the immune regulation and T-cell exhaustion in transient and persistent hepadnaviral infection. (31) Gender is known to be one of the major factors determining the outcome and severity of HBV infection, (1, 2) which could be confirmed with a cohort study (Supporting Fig. S14 ). However, how intrahepatic Tregs play a role in the pathogenesis of HBV infection is poorly understood. Previously, a small cohort of patients was examined for intrahepatic Tregs and the relationship to gender. (34) However, no significant difference between the genders was found. This is understandable as female patients more frequently clear HBV infection. Therefore, women unable to spontaneously clear HBV most likely have stronger T-cell dysfunction and, thus, may not show a significant difference from male patients.
Taken together, the magnitude of virus-specific CD8
1 T-cell responses in male mice was inversely correlated with hepadnaviral replication and protein levels and the number of intrahepatic Tregs. Induction of intrahepatic Tregs by enhanced hepadnaviral replication and protein levels may explain the gender-related differences in the outcomes of HBV infection. Moreover, the negative effect of Tregs on the HBV-specific T-cell response may result in lower efficacy of therapeutic immunomodulatory strategies in male patients. Therefore, functional blocking of Tregs may facilitate the control of HBV infection and improve the efficacy of immunotherapeutic approaches. 
